Particularly potent were combinations of INCB053914 with PI3K/AKT pathway inhibitors, chemotherapeutic agents including azacitidine, and small-molecule inhibitors including ibrutinib, that have utility in treating patients with hematologic malignancies. The gene discussed is AKT1; the disease is hematologic disorder.